title: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
abstract: Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.
authors.affiliation: Division of Nuclear Medicine, University Hospital, Sart Tilman, Liege, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Rigo
authors.forename: P
authors.initials: P
authors.lastname: Paulus
authors.forename: B J
authors.initials: BJ
authors.lastname: Kaschten
authors.forename: R
authors.initials: R
authors.lastname: Hustinx
authors.forename: T
authors.initials: T
authors.lastname: Bury
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
authors.forename: T
authors.initials: T
authors.lastname: Benoit
authors.forename: J
authors.initials: J
authors.lastname: Foidart-Willems
mesh_terms: D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
chemical_list: D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose